Poolbeg PharmaPOLBF -20.36% Current Ratio is 6.17 as of Dec. 2025, which is 55% below its 10-year median of 13.69. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Poolbeg Pharma ranks better than 64.71% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Poolbeg Pharma's current ratio for the quarter that ended in Dec. 2025 was 6.17.
Poolbeg Pharma has a current ratio of 6.17. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Poolbeg Pharma's Current Ratio or its related term are showing as below:
POLBF'
s Current Ratio Range Over the Past 10 Years
Min: 6.17 Med: 13.69 Max: 48.98
Current: 6.17
During the past 5 years, Poolbeg Pharma's highest Current Ratio was 48.98. The lowest was 6.17. And the median was 13.69.
POLBF's Current Ratio is ranked better than 64.71% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs POLBF: 6.17
Poolbeg Pharma (OTCPK:POLBF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Poolbeg Pharma Current Ratio Related Terms
Poolbeg Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POLBF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Poolbeg Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma (POLBF) has a Current Ratio of 6.17 as of Dec. 2025. This is 55% below median its historical median of 13.69. Over the past decade, Poolbeg Pharma's Current Ratio has ranged from 6.17 to 48.98. According to the industry distribution chart, Poolbeg Pharma ranks #500 out of 1417 companies in the Biotechnology industry, placing it in the top 35.3%.
Is Poolbeg Pharma's Current Ratio too high?
Poolbeg Pharma's current Current Ratio of 6.17 is 55% below median its 10-year median of 13.69. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 48.98. The Biotechnology industry median Current Ratio is 3.89. Poolbeg Pharma's value of 6.17 is 58.6% above this industry median. Based on the distribution chart, Poolbeg Pharma ranks #500 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint.
How does Poolbeg Pharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #500 out of 1417 companies for Current Ratio. This puts Poolbeg Pharma in the upper half of its industry. The industry median Current Ratio is 3.89. Poolbeg Pharma's value of 6.17 is 58.6% above this benchmark. Historically, Poolbeg Pharma's own Current Ratio has ranged from 6.17 to 48.98 over the past decade. While the company's 10-year median is 13.69 vs. the industry median of 3.89, Poolbeg Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poolbeg Pharma's current Current Ratio of 6.17 is 58.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Current Ratio is 6.17, which is 55% below median its own 10-year median of 13.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Current Ratio of 6.17. The current Current Ratio is 6.17, which is 55% below median its 10-year median of 13.69 and 58.6% above the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Current Ratio is 6.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 